(R,R)-LRRK2-IN-7_product_DataBase

Bioactivity	(R,R)-LRRK2-IN-7 is the isomer of LRRK2-IN-7 (HY-152107). LRRK2-IN-7 is a potent, selective, and CNS-penetrant LRRK2 kinase?inhibitor with an IC50 of 0.9 nM. LRRK2-IN-7 shows >1000-fold selectivity over other kinases, ion channels, and CYP enzymes[1].
Target	IC50: 0.9 nM (LRRK2 Kinase)
Invitro	LRRK2-IN-7 (compound 25) 既是小鼠乳腺癌抗性蛋白 (BCRP) 底物（小鼠/人 BCRP）也是一种有效的人 BCRP 抑制剂（BCRP IC50 = 0.12 μM）[1] .
In Vivo	在一项为期 7 天的大鼠剂量限制毒性研究中，LRRK2-IN-7 (compound 25) 的耐受性高达 100 mg/kg，每天一次（AUCtot = 330 μM·h）[1]。在大鼠急性（2 小时）PK/PD 研究中，LRRK2-IN-7 (compound 25) 显示大鼠脑纹状体中 LRRK2 pS935 剂量依赖性降低，EC50 = 0.18 nM[1]。
Name	(R,R)-LRRK2-IN-7
CAS	2307277-92-3
Formula	C24H26N6O
Molar Mass	414.50
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. David A Candito, et al. Discovery and Optimization of Potent, Selective, and Brain-Penetrant 1-Heteroaryl-1 H-Indazole LRRK2 Kinase Inhibitors for the Treatment of Parkinson's Disease. J Med Chem. 2022 Dec 22;65(24):16801-16817.

PeptideDB